Mitochondrial energetics in the kidney
Reads0
Chats0
TLDR
Implementing compounds that stimulate mitochondrial biogenesis can restore mitochondrial and renal function in mouse models of AKI and diabetes mellitus and inhibiting the fission protein dynamin 1-like protein (DRP1) might ameliorate ischaemic renal injury by blocking mitochondrial fission.Abstract:
The kidney requires a large number of mitochondria to remove waste from the blood and regulate fluid and electrolyte balance. Mitochondria provide the energy to drive these important functions and can adapt to different metabolic conditions through a number of signalling pathways (for example, mechanistic target of rapamycin (mTOR) and AMP-activated protein kinase (AMPK) pathways) that activate the transcriptional co-activator peroxisome proliferator-activated receptor-γ co-activator 1α (PGC1α), and by balancing mitochondrial dynamics and energetics to maintain mitochondrial homeostasis. Mitochondrial dysfunction leads to a decrease in ATP production, alterations in cellular functions and structure, and the loss of renal function. Persistent mitochondrial dysfunction has a role in the early stages and progression of renal diseases, such as acute kidney injury (AKI) and diabetic nephropathy, as it disrupts mitochondrial homeostasis and thus normal kidney function. Improving mitochondrial homeostasis and function has the potential to restore renal function, and administering compounds that stimulate mitochondrial biogenesis can restore mitochondrial and renal function in mouse models of AKI and diabetes mellitus. Furthermore, inhibiting the fission protein dynamin 1-like protein (DRP1) might ameliorate ischaemic renal injury by blocking mitochondrial fission.read more
Citations
More filters
Journal ArticleDOI
Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment.
TL;DR: More mechanistic studies are needed to better understand the convoluted pathophysiology of S-AKI and to translate these findings into potential treatment strategies and add to the promising pharmacologic approaches being developed and tested in clinical trials.
Journal ArticleDOI
Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance.
Meng Zhao,Yizhuo Wang,Ling Li,Shuyun Liu,Chengshi Wang,Yujia Yuan,Guang Yang,Younan Chen,Jingqiu Cheng,Yanrong Lu,Jingping Liu +10 more
TL;DR: In this article, the authors investigated the specific role of mtROS in initiating mitochondrial DNA (mtDNA) damage and inflammation during IRI-AKI, and they found that mt-ROS can promote renal injury by suppressing TFAM-mediated mtDNA maintenance, resulting in decreased mitochondrial energy metabolism and increased cytokine release.
Journal ArticleDOI
Sirtuins in Renal Health and Disease
TL;DR: An overview of the biologic effects of sirtuins and the molecular targets thereof regulating renal physiology is provided, highlighting the key role of SIRT1, SIRT3, and now SIRT6 as potential therapeutic targets.
Journal ArticleDOI
Mitochondrial quality control in kidney injury and repair.
Chengyuan Tang,Juan Cai,Xiao Ming Yin,Joel M. Weinberg,Manjeri A. Venkatachalam,Zheng Dong,Zheng Dong +6 more
TL;DR: The role of mitochondrial quality control mechanisms in kidney injury and repair is discussed and their potential as therapeutic targets are highlighted.
Journal ArticleDOI
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Lucas Opazo-Ríos,Sebastian Mas,Gema Marín-Royo,Sergio Mezzano,Carmen Gomez-Guerrero,Juan Antonio Moreno,Jesús Egido +6 more
TL;DR: This review examines the recent preclinical and clinical research about the potentially harmful effects of lipid effects in the kidney, metabolic markers associated with these mechanisms, major signaling pathways affected, the causes of excessive lipid accumulation, and the types of lipids involved, as well as offers a comprehensive update of therapeutic strategies targeting lipotoxicity.
References
More filters
Journal ArticleDOI
Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1α in db/db mice.
Yu Ah Hong,Ji Hee Lim,Min Young Kim,Tae Woo Kim,Yaeni Kim,Keun Suk Yang,Hoon Suk Park,Sun Ryoung Choi,Sungjin Chung,Hyung Wook Kim,Hye Won Kim,Bum Soon Choi,Yoon Sik Chang,Cheol Whee Park +13 more
TL;DR: The results suggest that fenofibrate improves lipotoxicity via activation of AMPK-PGC-1 α-ERR-1α-FoxO3a signaling, showing its potential as a therapeutic modality for diabetic nephropathy.
Journal ArticleDOI
Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations.
TL;DR: The data suggest that pharmacological activation of AMPK may enhance glucose uptake in individuals with type II diabetes, however, this benefit may be offset by the concomitant elevation in triglycerides.
Journal ArticleDOI
Mitochondrial dynamics and neurodegeneration
TL;DR: These studies establish mitochondrial dynamics as a new paradigm for neurodegenerattve disease research and compounds that modulate mitochondrial fission/fusion could have therapeutic value in disease intervention.
Journal ArticleDOI
mTORC1 maintains renal tubular homeostasis and is essential in response to ischemic stress
Florian Grahammer,Nora Haenisch,Frederic Steinhardt,Lukas Sandner,Malte Roerden,Frederic Arnold,Tomke Cordts,Nicola Wanner,Wilfried Reichardt,Dontscho Kerjaschki,Markus A. Rüegg,Michael N. Hall,Pierre Moulin,Hauke Busch,Melanie Boerries,Gerd Walz,Ferruh Artunc,Tobias B. Huber,Tobias B. Huber +18 more
TL;DR: Transcriptional profiling revealed that mTORC1 maintains renal tubular homeostasis by controlling mitochondrial metabolism and biogenesis as well as transcellular transport processes involved in countercurrent multiplication and urine concentration.
Journal ArticleDOI
Autophagy, Innate Immunity and Tissue Repair in Acute Kidney Injury.
TL;DR: The current pathophysiology of AKI is addressed in aspects of mitochondrial dysfunction, innate immunity, and molecular mechanisms of autophagy, which could lead to novel therapies in AKI.